FSB Premier Wealth Management Inc. Reduces Stock Position in Novartis AG (NYSE:NVS)

FSB Premier Wealth Management Inc. lessened its position in shares of Novartis AG (NYSE:NVS) by 3.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,532 shares of the company’s stock after selling 104 shares during the quarter. FSB Premier Wealth Management Inc.’s holdings in Novartis were worth $256,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in NVS. Mine & Arao Wealth Creation & Management LLC. boosted its position in shares of Novartis by 49.5% during the 2nd quarter. Mine & Arao Wealth Creation & Management LLC. now owns 299 shares of the company’s stock worth $30,000 after acquiring an additional 99 shares in the last quarter. Montag A & Associates Inc. lifted its holdings in shares of Novartis by 1.2% in the 2nd quarter. Montag A & Associates Inc. now owns 8,267 shares of the company’s stock valued at $834,000 after purchasing an additional 99 shares during the last quarter. Americana Partners LLC lifted its holdings in shares of Novartis by 0.7% in the 1st quarter. Americana Partners LLC now owns 14,826 shares of the company’s stock valued at $1,364,000 after purchasing an additional 100 shares during the last quarter. E&G Advisors LP lifted its holdings in shares of Novartis by 1.6% in the 2nd quarter. E&G Advisors LP now owns 6,398 shares of the company’s stock valued at $646,000 after purchasing an additional 100 shares during the last quarter. Finally, Physicians Financial Services Inc. lifted its holdings in shares of Novartis by 0.7% in the 2nd quarter. Physicians Financial Services Inc. now owns 14,083 shares of the company’s stock valued at $1,421,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 7.00% of the company’s stock.

Novartis Stock Performance

NVS traded up $1.23 on Tuesday, hitting $96.48. 215,547 shares of the company traded hands, compared to its average volume of 1,815,796. The company has a 50 day moving average of $97.21 and a 200-day moving average of $99.64. The company has a quick ratio of 0.83, a current ratio of 0.94 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $204.50 billion, a PE ratio of 25.60, a PEG ratio of 1.65 and a beta of 0.56. Novartis AG has a 12-month low of $79.98 and a 12-month high of $105.61.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Monday, October 23rd. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.70 by $0.04. The firm had revenue of $11.78 billion during the quarter, compared to the consensus estimate of $12.05 billion. Novartis had a return on equity of 28.27% and a net margin of 15.35%. During the same period in the prior year, the business earned $1.58 EPS. Sell-side analysts anticipate that Novartis AG will post 6.66 earnings per share for the current year.

Wall Street Analyst Weigh In

NVS has been the subject of several research reports. StockNews.com initiated coverage on Novartis in a report on Monday. They issued a “strong-buy” rating for the company. Morgan Stanley raised Novartis from an “underweight” rating to an “equal weight” rating in a report on Monday, September 25th. Four research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novartis presently has a consensus rating of “Moderate Buy” and an average target price of $84.50.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.